Agentix Corp. (AGTX): R&D Expense
$125.1K
Year ended 2026-03-31
$41.7K
Trailing 12 months to 2026-06-30
-44.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $125.1K | -30.9% | 2026-07-01, From 2025-04-01 |
| 2025-03-31 | $181.0K | +3.3% | 2026-07-01, From 2024-04-01 |
| 2024-03-31 | $175.3K | -75.4% | 2025-07-16, From 2023-04-01 |
| 2023-03-31 | $711.5K | +154.2% | 2024-08-30, From 2022-04-01 |
| 2022-03-31 | $279.9K | n/a | 2023-07-14, From 2021-04-01 |
| No annual figure between 2016-08-31 and 2022-03-31. | |||
| 2016-08-31 | $3.7K | -87.0% | 2017-12-18, From 2015-09-01 |
| 2015-08-31 | $28.3K | -54.1% | 2016-12-12, From 2014-09-01 |
| 2014-08-31 | $61.7K | n/a | 2015-12-16, From 2013-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Agentix Corp. (AGTX) | 2026-03-31 | $125.1K | -30.9% |
| Mosaic ImmunoEngineering Inc. (CPMV) | 2025-12-31 | $64.0K | -65.2% |
| Liminatus Pharma, Inc. (LIMN) | 2024-12-31 | $2.69M | n/a |
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $1.77M | -2.8% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $4.17M | -10.2% |
| Abpro Holdings, Inc. (ABPO) | 2025-12-31 | $989.0K | -66.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $10.25M | n/a |
Compare AGTX, CPMV, LIMN, APTN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗